Emre Misirlioglu Email

Chief Operating Officer . ConcR

Elmbridge,

Location

e***@concr.co

Primary Email

Current Roles

Employees:
13
Revenue:
$2M
About
Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland, our solutions are trusted by researchers in industry, academia and healthcare. Concr’s investors include the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Parkwalk Advisors, Deep Science Ventures and SyndicateRoom. The company has also received a grant from Innovate UK to trial Concr’s technology for improving treatment decision-making in clinic. The company’s HQ is in London, England, with a wholly owned subsidiary in Brisbane, Australia.
ConcR Address

Elmbridge, null
ConcR Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.